Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Integrin cytoplasmic tyrosine ... Parsons, J. T. et al. Focal adhesion kinase: Targeting adhesion signaling pathways for therapeutic intervention. Clinical Cancer Research 14, 627–632 (2008).
In conclusion, KLX exhibits protective effects against EndMT and atherosclerosis by activating the FGFR1/MAP4K4 pathway and suppressing the integrin β1/TGFβ signaling pathway. This study's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback